Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by Victory Capital Management Inc.

Victory Capital Management Inc. increased its holdings in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 328.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 50,460 shares of the company’s stock after acquiring an additional 38,690 shares during the period. Victory Capital Management Inc. owned approximately 0.07% of Perspective Therapeutics worth $674,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. WealthPlan Investment Management LLC purchased a new stake in shares of Perspective Therapeutics during the 3rd quarter worth $4,530,000. Hills Bank & Trust Co purchased a new stake in Perspective Therapeutics during the third quarter worth about $13,722,000. Nicholson Wealth Management Group LLC acquired a new position in Perspective Therapeutics during the third quarter worth about $21,390,000. WealthPLAN Partners LLC purchased a new position in Perspective Therapeutics in the second quarter valued at about $1,695,000. Finally, Bank of New York Mellon Corp lifted its position in shares of Perspective Therapeutics by 214.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 137,268 shares of the company’s stock valued at $1,369,000 after acquiring an additional 93,548 shares during the period. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. UBS Group assumed coverage on Perspective Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $20.00 price target on the stock. Royal Bank of Canada lowered their target price on Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating on the stock in a report on Monday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. Bank of America cut shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $24.00 to $5.00 in a research note on Monday. Finally, Oppenheimer cut their target price on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, November 22nd. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Perspective Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $15.14.

Perspective Therapeutics Price Performance

Shares of CATX stock opened at $4.12 on Friday. Perspective Therapeutics, Inc. has a twelve month low of $2.28 and a twelve month high of $19.05. The firm has a 50-day moving average price of $10.78 and a 200 day moving average price of $12.32.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The business had revenue of $0.37 million during the quarter. Equities analysts predict that Perspective Therapeutics, Inc. will post -0.87 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Johan M. Spoor bought 14,500 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were acquired at an average cost of $3.78 per share, with a total value of $54,810.00. Following the completion of the transaction, the chief executive officer now owns 152,072 shares of the company’s stock, valued at approximately $574,832.16. The trade was a 10.54 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Jonathan Robert Hunt bought 12,829 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was bought at an average price of $3.82 per share, with a total value of $49,006.78. Following the completion of the acquisition, the chief financial officer now owns 48,800 shares of the company’s stock, valued at $186,416. This trade represents a 35.66 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 33,595 shares of company stock valued at $126,625 in the last quarter. 3.52% of the stock is currently owned by company insiders.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.